Clinical Trial Update: Tianasen (ASO-GNAO1) for GNAO1-Encephalopathy With Epilepsy and Movement Disorders. [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 clinical trial evaluating Tianasen (ASO-GNAO1) for GNAO1-related encephalopathy presenting with epilepsy and movement disorders; currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Epilepsy
• Gnao1-related Encephalopathy
• Hyperkinetic Movement Disorders

Drugs mentioned

• Tianasen (ASO-GNAO1)

Snippet

Sponsor: Pirogov Russian National Research Medical University | Conditions: GNAO1, Epilepsy | Phase 1, Phase 2 | Status: RECRUITING